Summarized by Masters of Longevity from PR Newswire.
Company will report initial safety data from a Phase 1/2 diabetic foot ulcer trial.

Key Takeaways
- Initial safety data for CYWC628 is expected mid-December 2026.
- Interim efficacy data for CYWC628 is anticipated in February 2027.
- Findings are from a Phase 1/2 trial and are not causal.



